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Whatever the role of humoral mediators in acute 
inflammation, structural injury to tissues (as 
opposed to vasodilation. pain, and edema) cannot 
proceed without hydrolyt.ic degradation of ext.ra-
cellular and intracellular macromolecules . During 
the past two decades, it has become appreciated 
that. the degradative enzymes contained within 
Iysosomes of polymorphonuclear (PMN) leuko-
cytes are largely responsible for t he tissue damaO'e 
that accompanies inflammation [1 J. The~e 
enzymes are capable of hydrolyzing a wide variety 
of both natural and synthetic su bstrates, including 
slIDple and complex polysaccharides, oligopep-
tIdes, polypeptides, phosphate esters, lipids, 
etc. Whereas the relevance of most of these leuko-
cyte lysosomal hydrolases to the degradation of 
macromolecules in vivo remains controversial 
there is little doubt that neutral proteases and 
other chymotrypsin- like enzymes can cause irre-
versible tissue injury. These enzvmes have now 
been shown to be capable of degrading collagen 
(collagenase), elastin (elastase), carti lage proteo-
glycans, and lung connective tissue. In addition 
t he enzymes may act upon a variety of circulatin~ 
substrates t.o provoke either coagulation and/or 
fibrinolysis or the generation of biologically active 
products, such as low-molecular-weight comple-
ment-derived peptides (anaphylatoxins ) or kinins 
(Tab. n. 
That PMN leukocyte Iysosomes playa signifi-
cant role in provoking inflammation and tissue 
injury seems apparent. but the mechanisms where-
by the digestive enzymes within these membrane-
bound organelles are extruded from cells and gain 
access to their specific substrates have only re-
cently been delineated. Two such mechanisms 
have received considerable attention since they 
involve intact, viable cells and are amenable to 
modulation by a variety of pharmacologic agents. 
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Abbreviations: 
cAMP: cyclic 3' ,5'-adenosine monophosphate 
cGMP: cyclic 3',5 '-guanosine monophosphate 
PMN: polymorphonuclear 
MECHA:\\SMS OF LYSOSOMAL EI\ZYME RELE.~SE 
One mechanism of lysosomal enzyme relea e 
from intact, viable PMN leukocytes has been 
termed "regurgitation during feeding" [2J. This 
mechanism involves the release of lysosomal 
enzymes into the surrounding medium of in tact 
cells engaging in endocytosis (Fig.) , This release is 
not accompanied by leakage of cytoplasmic en-
zymes and appears to be due to the extrusion of ly-
sosomal materials from incompletely closed phag-
osomes, open at their external borders to the 
extracellular space but already joined at their 
internal borders by Iyso ames actively discharging 
thelT contents Into the vacuole. Regurgitation of 
lysosomal hydrolases occu rs and inflammatory 
matenals a re released into surrounding tissues 
without associated phagocytic cell death. Bio-
chemical and morphologic evidence for this mech-
anism has been presented for a variety of systems 
Involving particle ingestion by phagocytic cells. 
The other mechanism of selective lysosomal 
enzyme extrusion from intact PMN leuko~yt.es has 
been te rmed "reverse endocytosis" [3 ). This proc-
ess IS basically one in which material previously 
stored within Iysosomes i exported to the exte;-
nal milieu. PMN leukocytes. for example, which 
encounter immune complexes or aggregated im-
munoglobulins deposited upon solid surfaces such 
as Millipore filters or collagen membranes. adhere 
to these surfaces and selectively release their 
lysosomal constituents (Fig. J. Enzyme release 
under these conditions seems to occur by a process 
of reverse endocytosis (exocytosisl. during which 
merger of granules with the plasma membrane 
results in discharge of lysosomal enzymes directly 
to the outs ide of the cell as though into a phago-
cytic vacuole. Phagocytosis per se does not occur 
and the viability of the cells is not altered. 
Lysosomal enzyme release by the mechanism of 
"reverse endocytosis" has become amenable to 
more detailed analysis in cytochalasin B-treated 
PMN leukocytes. The fungal metabolite, cyto-
chalasin B. reversibly interferes with the function 
of cytoplasmic microfilaments and inhibits mem-
brane transport of sugars and nucleosides. Cyto-
chalasin B-treated PMN leukocytes are unable to 
ingest particles, but nevertheless release. or 
secrete, lysosomal but not. cytoplasmic enzymes 
when particles or other appropriate stimuli (e.g. , 
the complement component, C5a) come into con-
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TABLE I. Circulating substrates of leukocyte lysosomal enzymes 
Subst.rate 
Fibr inogen, fibrin 
Coagulation factors 
Plasminogen 
Bradykininogen 
C3 
C5 
~hogocyto,is 
.. 
C"rocholasin B 
Enzyme 
eutral protease 
Neutral protease 
Plasminogen activator 
Neutral protease 
Neutra l protease 
Neutral protease 
F IG. Mechan isms of se lective lysosomal enzyme re-
lease from intact. viable PMN leukocytes . 
tact with their surfaces [4 J (Fig. ). Ultrastructural 
and biochemical stud ies of cytochalasin B-treated 
cells have revealed membrane fusion between 
lysosomal granules and between these organelles 
and the plasma membrane as the morphologic 
accompaniment of biochemica lly measurable 
enzyme release_ Hence . cytochalasin B converts 
PMN leukocytes from phagocytic cells into model 
secretory cells. consequently making it possible to 
monitor extracellularly (after fusion of Iysosomes 
wi th plasma membranes) processes that ordinari ly 
occur intracellularly (fus ion of lysosomes with 
phagocyt.ic vacuoles). 
PHARMACOLOGIC MODCLATIO~ OF LYSOSOMAL 
E:--:ZY!v1E RELEA E 
Cytoc halasin B-treated PM!\, leukocytes 
exposed to the soluble complement component. 
Coa, have proved to be a useful experimental 
model system in which to study effects of phar-
macologic agents on lysosomal enzyme release 
from intact. cells. Effects of these agents on chemo-
taxis, surface adherence. and phagocytosis can be 
d isregarded in this system and thei r influe nce on 
the enzyme release process per se can be studied 
more directly. Consequently, if one assumes that 
t he manner in which C5a interacts with cells to 
provide the "signal " for exocytosis IS not. 
Biologic activity 
Fibrinolysis 
? Anti coagulant 
Fibrinolysis 
Kin in formation 
Chemotaxis 
Chemotaxis. anaphylatoxin formation , 
lysosomal enzyme release 
influenced by the pharmacologic agents under 
investigation (this mayor may not be correct), 
then any observed effects upon enzyme release 
may be in terpreted as being due to the agents ' 
influence upon organelle translocation or mem-
brane fusion . Three major types of compounds 
have been studied in this system: t hose t hat 
influence the accumulation within cells of cyclic 
nucleotides, i.e .. cyclic 3',5'-adenosine monopbos-
phate (cAMP) and cyclic 3',5'-guanosine mono-
phosphate (cGMP); t hose that affect the state or 
function of cytoplasmic microtubules; and those 
that are known to stabi lize biomembranes, i .e., 
adrena l cort icosteroids. Results of these studies are 
summarized in Table U. 
Exogenous cAMP (plus theophylline), as well as 
agents t ha t elevate cellular levels of cAMP (e.g., 
prostaglandin E 1. isoproterenol) reduce, whereas 
exogenous cGM P and agents that elevate levels of 
cGMP (e.g .. carbamylcholine, phorbol m~Tistate 
acetate) enhance lysosomal enzyme release from 
PMN leukocytes . Similarly, agents t ha t promote 
disassembly of cyt.oplasmic microt ubules (e .g. , 
colchicine, vinblastine) reduce, and agents tbat 
promote microtubule assembly (e.g .. deuterium 
oxide) enhance lysosomal enzyme re lease. Further -
more. cells stimulated to secrete lysosomal 
enzymes in the presence of C5a and cAMP (plus 
theophylline) show fewer microtubules t han in t he 
absence of t he cycl ic nucleotide. whereas cGMP 
appears to enhance the assembly of microtubules 
[9]. Although it has been tempting to suggest t hat 
a relationship exists between cyclic nucleotides. 
microt.ubules, and enzyme release from PM!\, leu-
kocytes. there is . as yet, no firm evidence to 
support this . In fac t , it is quite possible that the 
pharmacologic agents which have been studied 
exert t heir influence upon enzyme release by 
mechanisms which have not yet been recognized. 
Whatever the mechanism, it is clear that the 
reciprocal effects of cAMP (inhibition) and cGMP 
(enhancement ) upon lysosomal enzyme release 
from PM!\, leukocytes fi nd their correlates in dis-
assembly and assembly of cytoplasmic microtu-
buIes. 
Adrenal corticosteroids reduce lysosomal en-
zyme release from cvtochalas in B-t~eated human 
PMN leukocytes exPosed to Coa despite the ap-
pa rent inabili t.y of these compounds to affect the 
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T ABLE II. Modulation of leukocyte lysosomal 
enzyme release [4-81 
Agents that inhtbit release: 
cAMP 
Theophylline 
Prostagland in E. 
Cholera toxin 
Histamine 
Beta-adrenergic agonists 
Colchicine 
Vinblastine 
Adrenal corticosteroids 
Agents thaI enhan ce release: 
cGMP 
Cholinergic agonists 
Phorbol myristate acetate 
Deu terium oxide 
integrity of isolated lysosomal granules from these 
same cells flO J. One explanation for these find -
ings is that corticosteroids act to retard lysosomal 
enzyme release from intact. " iable cells by inhibit-
ing fusion of Iysosomes with their target mem -
branes. Such inhibition of membrane fusion may 
result from an increa e in pia rna membrane sta-
bility rather than from a direct effect upon Iyso-
somes. 
A indicated above. the effects of pharmacologic 
agents on specific events which occur in "stimu-
lated" cells often cannot be d ist inguished from 
effects on those stimulus-surface membrane in-
teractions which provide the "signals" for that 
Vol . 67, No.5, Part 2 of 2 parts 
specific event. Such is the case with t he effects of 
so-called microtubule agents, cyclic nucleotides, 
and corticosteroids on PMN leukocyte lysosomal 
enzyme release. Until it can be a certained with 
certainty that these compounds have no influence 
on the manner in which C5a (and other stimuli) 
interacts with these cells to provoke exocytosis, no 
firm conclusions can be drawn regarding the pre-
cise mechanisms by which t hey act. The possibility 
remains that these diverse pharmacologic agent 
can influence cellular functions by acting solely at 
the level of t.he surface membrane. 
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